Skip to main content
Clinical Trials/NCT04744974
NCT04744974CompletedPhase 2

A Randomized Clinical Trial to Assess the Impact of a Remotely Administered Diet Intervention on Symptom Burden and Inflammatory Cytokines in Myeloproliferative Neoplasm: Feasibility Phase

University of California, Irvine1 site in 1 country28 target enrollmentStarted: January 21, 2021Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
28
Locations
1
Primary Endpoint
MPN Symptom Assessment form (MPN-SAF)

Study Overview

Brief Summary

Myeloproliferative Neoplasm (MPN) is a chronic blood cancer without cure. The major clinical issues in MPN are 1) an increased risk of blood clots 2) symptoms thought to be driven by chronic inflammation which in some cases can be debilitating and 3) progression to acute leukemia. The current management of MPN focuses on preventing blood clots and relieving symptoms. However, treatments that reduce symptoms such as JAK inhibitors are limited to late stage MPN patients and have significant side effects including immunosuppression, reduction in platelets, and increased risk of skin cancer. Therefore, low risk interventions are sorely needed for MPN patients that can reduce symptoms. Diet represents a low risk way to reduce inflammation, specifically a Mediterranean diet has been found to reduce inflammation in cardiovascular disease. There has been a recently completed clinical trial that demonstrated MPN patients can adopt a Mediterranean diet if given dietician counseling and curriculum. However, in order to reach a larger group of people a fully remotely administered study is necessary. This is a feasibility study to determine.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Participant)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age ≥18 with a diagnosis of a Philadelphia chromosome negative Myeloproliferative Neoplasm (MPN) including Essential Thrombocythemia (ET), Polycythemia Vera (PV), or Myelofibrosis (MF)
  • •Has access to the internet and email
  • •MPN-Total Symptom Score (MPN-TSS) score of ≥10 on screening survey
  • •Mediterranean Adherence score of ≤10 on screening survey
  • •English fluency (intervention requires conversations with study staff)
  • •In the opinion of the study team is amenable to changing one's diet

Exclusion Criteria

  • •Pregnant or planning to become pregnant over the course of the study
  • •Has food allergies, intolerances, or other dietary restrictions which would severely limit changes to their diet toward a Mediterranean style diet (such as allergies to ALL tree nuts or olive oil)

Arms & Interventions

Mediterranean diet

Experimental

Participants will be given dietician counseling on a Mediterranean diet

Intervention: Diet intervention (Behavioral)

DASH diet

Experimental

Participants will be given dietician counseling on a DASH diet

Intervention: Diet intervention (Behavioral)

Outcomes

Primary Outcomes

MPN Symptom Assessment form (MPN-SAF)

Time Frame: 16 weeks

validated survey tool to assess symptom burden in MPN

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Angela G. Fleischman

Associate Professor, Division of Hematology/Oncology, Medicine

University of California, Irvine

Study Sites (1)

Loading locations...

Similar Trials